

Global Ibrutinib API Market Growth 2023-2029

<https://marketpublishers.com/r/GC61F6FF43C0EN.html>

Date: March 2023

Pages: 96

Price: US\$ 3,660.00 (Single User License)

ID: GC61F6FF43C0EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Ibrutinib is an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.

LPI (LP Information)' newest research report, the "Ibrutinib API Industry Forecast" looks at past sales and reviews total world Ibrutinib API sales in 2022, providing a comprehensive analysis by region and market sector of projected Ibrutinib API sales for 2023 through 2029. With Ibrutinib API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Ibrutinib API industry.

This Insight Report provides a comprehensive analysis of the global Ibrutinib API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ibrutinib API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Ibrutinib API market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ibrutinib API and breaks down the forecast by type, by

application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ibrutinib API.

The global Ibrutinib API market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Ibrutinib API is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Ibrutinib API is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Ibrutinib API is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Ibrutinib API players cover Dr. Reddy's Laboratories Ltd., Teva API, Shilpa Medicare Limited, Wisdom Pharmaceutical Co., Ltd., ScinoPharm Taiwan, Ltd, Sun Pharmaceutical Industries Ltd. and Haoyuan Chemexpress, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Ibrutinib API market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Purity?98%

Purity

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Ibrutinib API Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Ibrutinib API by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Ibrutinib API by Country/Region, 2018, 2022 & 2029
- 2.2 Ibrutinib API Segment by Type
 - 2.2.1 Purity?98%
 - 2.2.2 Purity

List Of Tables

LIST OF TABLES

Table 1. Ibrutinib API Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Ibrutinib API Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Purity?98%

Table 4. Major Players of Purity

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Ibrutinib API

Figure 2. Ibrutinib API Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Ibrutinib API Sales Growth Rate 2018-2029 (Ton)

Figure 7. Global Ibrutinib API Revenue Growth Rate 2018-2029 (\$ Millions)

Figure 8. Ibrutinib API Sales by Region (2018, 2022 & 2029) & (\$ Millions)

Figure 9. Product Picture of Purity?98%

Figure 10. Product Picture of Purity

I would like to order

Product name: Global Ibrutinib API Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GC61F6FF43C0EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC61F6FF43C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970